Prostate cancer cells
Chicago—Two Phase III trials elucidate the role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC). In one trial, cabazitaxel failed to provide an overall survival (OS) or progression-free survival (PFS) advantage over docetaxel in first-line therapy for mCRPC. In the other, which compared doses of cabazitaxel for second-line chemotherapy, the 20-mg/m2 dose was as effective as the 25-mg/m2 dose but less toxic.
Both data sets